A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2022-10-10
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-12-04 (study day 41); relationship: N
mild
assessed
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-10 (study day 47); relationship: not assessed
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-12 (study day 139); relationship: N
Data queries
No data queries.